Results 51 to 60 of about 2,325 (161)

Delivery of thymoquinone to cancer cells with as1411-conjugated nanodroplets.

PLoS ONE, 2020
Systemic delivery of conventional chemotherapies can cause negative systemic toxicity, including reduced immunity and damage to organs such as the heart and kidneys-limiting the maximum dose that can be administered.
Emily M Murphy, Connor S Centner, Paula J Bates, Mohammad T Malik, Jonathan A Kopechek   +4 more
doaj   +1 more source

A multi-storey DNA nanostructure containing doxorubicin and AS1411 aptamer for targeting breast cancer cells

Journal of Drug Targeting, 2022
Herein, we presented a novel DOX-loaded multi-storey DNA nanostructure, including AS1411 aptamer as a targeting agent for treatment of target cells (MCF-7 and 4T1). Gel retardation test and fluorometric analysis were used to examine the construction of DNA nanostructure and loading of DOX in the complex.
Elnaz Yaghoobi, TaranehSadat Zavvar, Mohammad Ramezani, Mona Alibolandi, Sara Rahimzadeh Oskuei, Mahsa Zahiri, Morteza Alinezhad Nameghi, Khalil Abnous, Seyed Mohammad Taghdisi   +8 more
openaire   +2 more sources

Delivery Systems for Therapeutic Genome Editing: Challenges, Innovations, and Future Perspectives

MedComm, Volume 7, Issue 7, July 2026.
Schematic illustration of four emerging CRISPR–Cas delivery platforms defined by distinct design principles and structural features: virus‐mimicking nanosystems (e.g., VLPs), cell‐derived extracellular vesicles, cell‐penetrating peptides, and stimuli‐responsive scaffolds. These platforms enable spatiotemporally controlled delivery of RNPs, mRNA, or DNA
Meijia Yang, Yiqiong Song, Ziyang Wang, Ke Chao, Lifeng Li, Xu Zhang, Xiaoran Duan, Chenglong Yu, Ruyue Xue, Jie Zhao   +9 more
wiley   +1 more source

Molecularly engineered truncated tissue factor with therapeutic aptamers for tumor-targeted delivery and vascular infarction

Acta Pharmaceutica Sinica B, 2021
Selective occlusion of tumor vasculature has proven to be an effective strategy for cancer therapy. Among vascular coagulation agents, the extracellular domain of coagulation-inducing protein tissue factor, truncated tissue factor (tTF), is the most ...
Bozhao Li, Jingyan Wei, Chunzhi Di, Zefang Lu, Feilong Qi, Yinlong Zhang, Wei Sun Leong, Lele Li, Guangjun Nie, Suping Li   +9 more
doaj   +1 more source

Proteomic Characterization of AS1411 Reveals ATP6AP1 as a Mediator of Triple‐Negative Breast Cancer Progression

PROTEOMICS, Volume 26, Issue 7, Page 28-41, July 2026.
ABSTRACT Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by high metastatic potential, poor prognosis, and limited effective therapeutic options. In this study, we investigated the molecular mechanisms underlying the anticancer effects of the nucleolin (NCL)‐targeting DNA aptamer AS1411 using label‐free ...
Ha‐Song Bae, Yun‐Jeong Seo, Eun‐Bi Kim, Hyoung‐Min Park, I‐Hsuan Liu, J. Eugene Lee, Jae‐Young Kim   +6 more
wiley   +1 more source

Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy

Cancer Nanotechnology, 2023
Background Immune checkpoint blockade (ICB) is a promising strategy for cancer treatment and has achieved remarkable clinical results. Further improvement of ICB efficacy may advance cancer immunotherapy and has evident medical importance.
Junjun Fu, Fengjiao Yao, Yacong An, Xundou Li, Wenya Wang, Xian-Da Yang   +5 more
doaj   +1 more source

Engineering Extracellular Vesicles for Anti‐Aging Therapy: Mechanisms, Applications, and Perspectives

Aging Cell, Volume 25, Issue 7, July 2026.
This review systematically elucidates the multifactorial anti‐aging mechanisms of extracellular vesicles (EVs). By bridging fundamental biology with advanced bioengineering, scalable manufacturing, and clinical translation, it establishes a comprehensive framework for developing next‐generation EVs‐based precision nanotherapeutics to combat systemic ...
Xian Huang, Qiujie Li, Guofang Tao, Xulin Gan, Jiangjie Lu, Sergei Krasny, Liyun Shi   +6 more
wiley   +1 more source

Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects

Advanced Science, Volume 13, Issue 36, 29 June 2026.
Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu, Ke Wang, Kaizhong Lu, Tianlun Hou, Yuan Chen, Xian Wang, Hongchuan Jin   +6 more
wiley   +1 more source

Aptamer train formed by hybridization and enzymatic ligation for specifically delivering MTZ to colon cancer cells

Results in Chemistry
Multivalent interactions enhance targeted drug delivery by enabling stronger, specific binding to overexpressed receptors on target cells. This multivalent approach improves targeting efficiency, increases local drug concentration, and reduces off-target
Kanpitcha Jiramitmongkon, Pichayanoot Rotkrua, Paisan Khanchaitit, Jiraporn Arunpanichlert, Boonchoy Soontornworajit   +4 more
doaj   +1 more source

Mimic, target, and adapt: Cell membrane‐coated nanoplatforms for precision and immune‐guided cancer treatment

BMEMat, Volume 4, Issue 2, June 2026.
This Perspective explores the emerging landscape of cell membrane‐coated nanoparticles (CM‐NPs) as intelligent, immune‐compatible platforms for cancer therapy. Highlighting design strategies, translational challenges, and competitive positioning, it outlines how integrating biomimetic targeting with advanced analytical and manufacturing tools could ...
A. K. M. M. Alam, Xiaojun Cai, Malik Ihsan Ullah Khan, Robert Musiol, Quazi T. H. Shubhra   +4 more
wiley   +1 more source